Please click here for UK prescribing information and adverse event reporting information

This is a promotional material fully funded by Bayer and is intended for UK healthcare professionals only. EYLEA (aflibercept) 8 mg is indicated in adults for the treatment of nAMD, visual impairment due to DMO and visual impairment due to macular oedema secondary to RVO (branch, central and hemiretinal RVO). Please refer to the licensed EYLEA 8 mg SmPC for the full licensed posology and the full summary of the safety profile.

Site logo
Bayer logo

EYLEA® (aflibercept) 8 mg

Evidence Explorer

Select a region to reveal findings

  • Home icon
  • Performance you can trust
  • Global data
  • UK data
Click select icon
  • Performance You Can Trust
  • Global real-world evidence
  • UK real-world evidence

DMO, diabetic macular oedema; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; SmPC, Summary of Product Characteristics.

May 2026 | PP-EYL_8mg-GB-1055

Modal close icon

Prescribing information

UK prescribing information and adverse event reporting information for EYLEA® (aflibercept) 40 mg/mL and 114.3 mg/mL solution for injection is available via the QR codes below. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

Prescribing information qr 1

EYLEA® (aflibercept)
40 mg/mL

Prescribing information qr 2

EYLEA® (aflibercept)
114.3 mg/mL

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to Bayer plc. If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.

Produced and funded by Bayer.